Company Overview and News

 
Banks, traders launch first commodities blockchain platform

47m theedgemarkets
LONDON (Sept 19): Global banks and trading firms are launching the first blockchain-based platform for financing the trading of commodities from oil to wheat, they said in a joint statement on Wednesday.
BNPZY SCGLF BNPQY SCGLY GLE BNPQF

 
Oil Near Week's High as Supply Data Tempers Saudi View on Prices

1h rigzone
(Bloomberg) -- Brent oil held near the highest level in a week as investors weighed a potential gain in U.S. crude stockpiles against Saudi Arabia’s comfort with prices rising above $80 a barrel.
BNPZY BNPQY BNPQF

 
Investing in MFs to become cheaper on SEBI move, AMC margins may be affected: Experts

1h moneycontrol
Investing in mutual funds will become cheaper, while margins of asset management companies may get affected due to regulator SEBI's move to slash the charges levied on investors, experts said.
BNPZY BNPQY BNPQF

 
Should Value Investors Buy BNP Paribas (BNPQY) Stock?

1h zacks
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
BNPZY BNPQY BNPQF

 
Banks, traders launch first commodities blockchain platform

2h channelnewsasia
LONDON: Global banks and trading firms are launching the first blockchain-based platform for financing the trading of commodities from oil to wheat, they said in a joint statement on Wednesday.
BNPZY SCGLF BNPQY SCGLY GLE BNPQF

 
RIL plans to set up Reliance Jio Hubs to boost sales in smaller towns

10h livemint
New Delhi: India’s richest man Mukesh Ambani plans to build Reliance Jio Hubs, a one-stop shop for all consumer items sold by Reliance Industries Ltd and its units ranging from electronics to groceries, to provide people living in small towns their first mall-like shopping experience. The aim is to leverage the strengths of units Reliance Retail Ltd’s physical stores and Reliance Jio Infocomm Ltd’s digital infrastructure to boost sales in smaller towns, which have largely been untouched by modern retail and online shopping.
BNPZY 500325 BNPQY RELIANCE RIGD BNPQF RLNIY

 
Danske Bank: Money Laundering Issues Pullback Might Present A Good Entry Point

20h seekingalpha
Danske Bank's (OTCPK:DNSKF; OTCPK:DNKEY) share price has been in free fall following the opening of an internal investigation related to potential money laundering activities in its Estonian branch. Danish authorities have not pressed any criminal charges against Danske Bank because of a lack of evidence but the Danish FSA has issued 8 reprimands and has increased the bank's capital requirement. As a result, the stock has underperformed its Nordics peers by at least 25% on a year-to-date basis.
BNPZY BNPQY BNPQF

7
As Fiscal Stimulus Fades, What's Next?

2018-09-17 seekingalpha
To date, markets have largely ignored the impact of increasing dollar values of tariffs given strong corporate earnings year to date.
BBVA BNPZY NAT SBLKL BNPQY BNPQF LNG SBLK

3
IPO News This Week: 8 Firms Looking to Capital Markets for $3.26 Billion

2018-09-16 247wallst - 3
Last week’s initial public offering (IPO) action saw five companies launch successful offerings that raised $1.33 billion in new capital. A total of eight IPOs are scheduled to launch in the coming week seeking a total of more than $3.26 billion in new capital. In addition to the five IPOs, five more firms set terms last week.
NIO QTT DB PRNB BNPQY DTK BNPQF BNPZY FVCB MS

 
Exclusive: Saudi Arabia to auction detained tycoon's real estate assets - sources

2018-09-16 channelnewsasia
Saudi Arabia will auction real estate owned by indebted billionaire Maan al-Sanea and his company starting next month to help repay billions of riyals due to creditors, sources familiar with the matter told Reuters.
BNPZY BNPQY BNPQF

 
Exclusive: Saudi Arabia to auction detained tycoon's real estate assets - sources

2018-09-16 reuters
RIYADH (Reuters) - Saudi Arabia will auction real estate owned by indebted billionaire Maan al-Sanea and his company starting next month to help repay billions of riyals due to creditors, sources familiar with the matter told Reuters.
BNPZY BNPQY BNPQF

 
U.S. Q3 GDP Growth On Track For Slower But Still Healthy Pace

2018-09-14 seekingalpha
The surge in US economic output in the second quarter is expected to moderate in Q3, based on a set of nowcasts compiled by The Capital Spectator. The median estimate continues to anticipate a healthy 3.2% increase for Q3, slightly below the median projection in late-August.
BNPZY BNPQY BNPQF

 
Turkey raising rates is 'not the solution,' Mark Mobius warns

2018-09-14 cnbc
Turkey's raising of interest rates won't boost confidence in its economy, asset manager Mark Mobius warned Friday.
BNPZY BNPQY BNPQF

 
Oil prices rise as focus returns to supply concerns

2018-09-14 reuters
LONDON (Reuters) - Oil rose on Friday, clawing back some territory after prices fell by the most in a month in the previous session, as the focus returned to supply concerns ahead of a November deadline for U.S. sanctions on Iranian crude.
BNPZY BNPQY BNPQF

 
'Turkey is great': BNP Paribas chairman says his bank is not pulling out of the troubled country

2018-09-14 cnbc
Despite the economic challenges facing Turkey that have sent the lira on a dramatic fall, the country remains a "great" market that BNP Paribas has no intention of exiting, the French bank's chairman said on Friday.
BNPZY BNPQY BNPQF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 05565A202